The parenteral route of administration will generate revenue worth over USD 3.5 billion by end of 2032, as injections and intravenous infusion offer direct & rapid delivery of infertility drugs into the bloodstream, ensuring more efficient & predictable absorption of the drugs, faster onset of action, and improved treatment outcomes. Read More